Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma: Recent FDA Setbacks Present A Buying Opportunity
10:56pm, Sunday, 16'th Apr 2023
We are upgrading from a hold to buy rating for ASND following a 35% drop in stock price after FDA deficiency findings in the NDA for TransCon PTH for hyperparathyroidism. We expect potential US FDA ap
Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27
08:30am, Thursday, 13'th Apr 2023
COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, April 27, 2023, at
Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?
10:40am, Wednesday, 12'th Apr 2023
Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more
Why Ascendis Pharma Stock Is Crashing This Week
04:22pm, Thursday, 06'th Apr 2023
The FDA found deficiencies with Ascendis' regulatory filing for TransCon PTH in treating hypoparathyroidism. Ascendis plans to talk with the FDA to learn more about the issues and hopefully address th
Ascendis Pharma: Is Dip On TransCon Application A Buy Opportunity?
03:11pm, Thursday, 06'th Apr 2023
Ascendis has enjoyed a market cap valuation of >$6bn thanks to its TransCon technology platform and single approved asset SKYTROFA. SKYTROFA is approved for growth hormone deficiency as a once-weekly
Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies
02:28pm, Tuesday, 04'th Apr 2023
The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.
Why Ascendis Pharma Stock Is Plunging Today
12:28pm, Monday, 03'rd Apr 2023
The FDA has identified deficiencies in Ascendis' regulatory filing for the hypoparathyroidism candidate TransCon PTH. With little info on the nature of the deficiencies, investors are moving to the si
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
Ascendis Pharma A/S (ASND) Q4 2022 Earnings Call Transcript
11:10pm, Thursday, 16'th Feb 2023
Ascendis Pharma A/S (ASND) Q4 2022 Results Conference Call February 16, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director of Investor Relations Jan Mikkelsen - President and Chief Executi
Ascendis Pharma: Group's Best Nearby Capital Gain Price-Position Stock
10:36pm, Wednesday, 18'th Jan 2023
This is an article about stock prices more than about healthcare technologies, which have been extensively considered by those with appropriate expertise. 21st Century advances on 20th century medical
Ascendis Pharma A/S (ASND) Q3 2022 Earnings Call Transcript
10:15pm, Friday, 04'th Nov 2022
Ascendis Pharma A/S (ASND) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President & Chief Executive O
Ascendis Pharma: Translating Valuable IP Into A Profitable Business
12:17pm, Friday, 04'th Nov 2022
Ascendis Pharma has one commercial product and another with a PDUFA date in early 2023 and a path to profitability. The validated platform has produced best in class medicines and in Q4 there will be
Ascendis Pharma: TransCon CNP Data Coming Q4
12:42pm, Thursday, 15'th Sep 2022
Ascendis Pharma is now a commercial-stage company with a full pipeline and a revenue stream. There are multiple upcoming catalysts, including oncology data due by year end, which may validate the brea
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2022 Results - Earnings Call Transcript
10:36pm, Wednesday, 10'th Aug 2022
Ascendis Pharma A/S (ASND) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive
Why Ascendis Pharma Stock Is Sinking Today
12:46pm, Thursday, 12'th May 2022
Investors are reacting negatively to the company's Q1 update.
